| Assay ID | Title | Year | Journal | Article |
|---|
| AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
| High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
| Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | | | |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4
| A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1312305 | Clearance in Lewis rat at 1 mg/kg, iv measured up to 24 hrs by LC-MS/MS analysis | 2016 | Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
| Development of Autotaxin Inhibitors: An Overview of the Patent and Primary Literature. |
| AID1908645 | Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay | 2022 | European journal of medicinal chemistry, Jun-05, Volume: 236 | Design, synthesis and promising anti-tumor efficacy of novel imidazo[1,2-a]pyridine derivatives as potent autotaxin allosteric inhibitors. |
| AID1497190 | Equilibrium solubility of compound at pH 6.8 by high-throughput screening method | 2018 | Bioorganic & medicinal chemistry letters, 07-15, Volume: 28, Issue:13
| Development of autotaxin inhibitors: A series of zinc binding triazoles. |
| AID1633001 | Inhibition of autotaxin in healthy human plasma assessed as reduction in LPA level after 3 hrs by mass spectrometric analysis | 2016 | ACS medicinal chemistry letters, Sep-08, Volume: 7, Issue:9
| Novel Autotaxin Inhibitors for the Treatment of Osteoarthritis Pain: Lead Optimization via Structure-Based Drug Design. |
| AID1488986 | Inhibition of recombinant human ATX beta expressed in HEK293 cells using LPC as substrate measured after 30 mins by LC-MS/MS analysis | 2017 | Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17
| Design, synthesis, docking and biological evaluation of 4-phenyl-thiazole derivatives as autotaxin (ATX) inhibitors. |
| AID1908948 | Inhibition of rat ATX lysoPLD activity using LPC as substrate assessed as reduction in choline release measured after 60 mins by HVA fluorescence based analysis | 2022 | Journal of medicinal chemistry, 04-28, Volume: 65, Issue:8
| Structure-Based Design of a Novel Class of Autotaxin Inhibitors Based on Endogenous Allosteric Modulators. |
| AID1488987 | Inhibition of recombinant human ATX beta expressed in HEK293 cells using FS-3 as substrate pretreated for 15 mins followed by substrate addition measured after 30 mins | 2017 | Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17
| Design, synthesis, docking and biological evaluation of 4-phenyl-thiazole derivatives as autotaxin (ATX) inhibitors. |
| AID1312309 | Plasma concentration in Lewis rat air pouch model of inflammation at 3 mg/kg, po administered through gavage 1 hr before carrageenan injection measured after 3 hrs by LC-MS/MS analysis relative to control | 2016 | Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
| Development of Autotaxin Inhibitors: An Overview of the Patent and Primary Literature. |
| AID1497192 | Inhibition of ATX (unknown origin) assessed as decrease in choline release | 2018 | Bioorganic & medicinal chemistry letters, 07-15, Volume: 28, Issue:13
| Development of autotaxin inhibitors: A series of zinc binding triazoles. |
| AID1497193 | Permeability assessed as drug absorption at 50 ug/ml after 5 hrs by PAMPA | 2018 | Bioorganic & medicinal chemistry letters, 07-15, Volume: 28, Issue:13
| Development of autotaxin inhibitors: A series of zinc binding triazoles. |
| AID1633000 | Inhibition of recombinant full length human C-terminal His-tagged autotaxin expressed in human 293E cells assessed as choline release using lysophosphatidylcholine as substrate after 1 hr by Amplex red fluorescence assay | 2016 | ACS medicinal chemistry letters, Sep-08, Volume: 7, Issue:9
| Novel Autotaxin Inhibitors for the Treatment of Osteoarthritis Pain: Lead Optimization via Structure-Based Drug Design. |
| AID1632555 | Inhibition of recombinant ATX (unknown origin) expressed in HEK293 cells using FS-3 as substrate after 15 mins | 2016 | Bioorganic & medicinal chemistry, 10-01, Volume: 24, Issue:19
| Discovery and synthetic optimization of a novel scaffold for hydrophobic tunnel-targeted autotaxin inhibition. |
| AID1480297 | In vivo inhibition of ATX in Lewis rat assessed as decrease in plasma LPA levels at 30 mg/kg administered via oral gavage measured over 4 hrs LC-MS/MS method relative to control | 2018 | Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
| Hydroxamic Acids Constitute a Novel Class of Autotaxin Inhibitors that Exhibit in Vivo Efficacy in a Pulmonary Fibrosis Model. |
| AID1633008 | Inhibition of autotaxin in healthy human whole blood assessed as reduction in LPA level after 2 hrs by LC-MS/MS analysis | 2016 | ACS medicinal chemistry letters, Sep-08, Volume: 7, Issue:9
| Novel Autotaxin Inhibitors for the Treatment of Osteoarthritis Pain: Lead Optimization via Structure-Based Drug Design. |
| AID1480294 | Inhibition of recombinant mouse ATX expressed in HEK293 cells using FS3 as substrate preincubated for 15 mins followed by substrate addition measured after 30 mins | 2018 | Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
| Hydroxamic Acids Constitute a Novel Class of Autotaxin Inhibitors that Exhibit in Vivo Efficacy in a Pulmonary Fibrosis Model. |
| AID1908646 | Cytotoxicity against human NCI-H1581 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay | 2022 | European journal of medicinal chemistry, Jun-05, Volume: 236 | Design, synthesis and promising anti-tumor efficacy of novel imidazo[1,2-a]pyridine derivatives as potent autotaxin allosteric inhibitors. |
| AID1325587 | Inhibition of human recombinant ATX using Rac-1-Palmitoyl-glycero-3-phosphocholine as substrate incubated for 2 hrs using ADHP fluorogenic peroxidase substrate by horseradish peroxidase/choline oxidase-coupled assay | 2016 | Bioorganic & medicinal chemistry letters, 11-15, Volume: 26, Issue:22
| Discovery of potent inhibitors of the lysophospholipase autotaxin. |
| AID1739783 | Inhibition of human C-terminal His6-tagged ATX beta expressed in Sf9 insect cells using FS-3 as substrate preincubated for 45 mins followed by substrate addition and measured at 1 min interval for 30 mins by fluorescence assay | 2020 | European journal of medicinal chemistry, Sep-01, Volume: 201 | Structure guided design of potent indole-based ATX inhibitors bearing hydrazone moiety with tumor suppression effects. |
| AID1739787 | Antiproliferative activity against human NCI-H2228 cells measured after 72 hrs by MTT assay | 2020 | European journal of medicinal chemistry, Sep-01, Volume: 201 | Structure guided design of potent indole-based ATX inhibitors bearing hydrazone moiety with tumor suppression effects. |
| AID1325588 | Inhibition of ATX in human plasma assessed as decrease in hydrolysis of lysophosphatidylcholine by measuring choline release after 24 hrs by horseradish peroxidase/choline oxidase-coupled assay | 2016 | Bioorganic & medicinal chemistry letters, 11-15, Volume: 26, Issue:22
| Discovery of potent inhibitors of the lysophospholipase autotaxin. |
| AID1908649 | Cytotoxicity against mouse RAW264.7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay | 2022 | European journal of medicinal chemistry, Jun-05, Volume: 236 | Design, synthesis and promising anti-tumor efficacy of novel imidazo[1,2-a]pyridine derivatives as potent autotaxin allosteric inhibitors. |
| AID1908644 | Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay | 2022 | European journal of medicinal chemistry, Jun-05, Volume: 236 | Design, synthesis and promising anti-tumor efficacy of novel imidazo[1,2-a]pyridine derivatives as potent autotaxin allosteric inhibitors. |
| AID1349341 | Inhibition of human ERG expressed in HEK293 cells by patch clamp assay | 2017 | ACS medicinal chemistry letters, Dec-14, Volume: 8, Issue:12
| Discovery of BI-2545: A Novel Autotaxin Inhibitor That Significantly Reduces LPA Levels in Vivo. |
| AID1312304 | Effective half life in Lewis rat at 1 mg/kg, iv measured up to 24 hrs by LC-MS/MS analysis | 2016 | Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
| Development of Autotaxin Inhibitors: An Overview of the Patent and Primary Literature. |
| AID1349340 | Inhibition of ATX in rat whole blood using LPA 17:0 as substrate after 1 hr by LC-MS/MS analysis | 2017 | ACS medicinal chemistry letters, Dec-14, Volume: 8, Issue:12
| Discovery of BI-2545: A Novel Autotaxin Inhibitor That Significantly Reduces LPA Levels in Vivo. |
| AID1497189 | Oral bioavailability in Lewis rat at 1 to 100 mg/kg dosed via gavage after 1.25 to 24 hrs | 2018 | Bioorganic & medicinal chemistry letters, 07-15, Volume: 28, Issue:13
| Development of autotaxin inhibitors: A series of zinc binding triazoles. |
| AID1908643 | Cytotoxicity against human MCF-7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay | 2022 | European journal of medicinal chemistry, Jun-05, Volume: 236 | Design, synthesis and promising anti-tumor efficacy of novel imidazo[1,2-a]pyridine derivatives as potent autotaxin allosteric inhibitors. |
| AID1312310 | Plasma concentration in Lewis rat air pouch model of inflammation at 100 mg/kg, po administered through gavage 1 hr before carrageenan injection measured after 3 hrs by LC-MS/MS analysis relative to control | 2016 | Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
| Development of Autotaxin Inhibitors: An Overview of the Patent and Primary Literature. |
| AID1739785 | Antiproliferative activity against human MDA-MB-231 cells measured after 72 hrs by MTT assay | 2020 | European journal of medicinal chemistry, Sep-01, Volume: 201 | Structure guided design of potent indole-based ATX inhibitors bearing hydrazone moiety with tumor suppression effects. |
| AID1656153 | Inhibition of human ATX pre-incubated for 45 mins before fluorogenic substrate-3 addition and measured every minute for 30 mins by fluorescence based assay | 2020 | Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13
| Discovery of Novel Indole-Based Allosteric Highly Potent ATX Inhibitors with Great |
| AID1908648 | Cytotoxicity against human Hep3B cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay | 2022 | European journal of medicinal chemistry, Jun-05, Volume: 236 | Design, synthesis and promising anti-tumor efficacy of novel imidazo[1,2-a]pyridine derivatives as potent autotaxin allosteric inhibitors. |
| AID1739784 | Antiproliferative activity against human MCF7 cells measured after 72 hrs by MTT assay | 2020 | European journal of medicinal chemistry, Sep-01, Volume: 201 | Structure guided design of potent indole-based ATX inhibitors bearing hydrazone moiety with tumor suppression effects. |
| AID1438632 | Inhibition of human ATX expressed in HEK293 cells using FS-3 as substrate after 15 mins | 2017 | Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
| Rational Design of Autotaxin Inhibitors by Structural Evolution of Endogenous Modulators. |
| AID1739786 | Antiproliferative activity against human A549 cells measured after 72 hrs by MTT assay | 2020 | European journal of medicinal chemistry, Sep-01, Volume: 201 | Structure guided design of potent indole-based ATX inhibitors bearing hydrazone moiety with tumor suppression effects. |
| AID1312308 | Invivo inhibition of ATX in Lewis rat air pouch model of inflammation assessed as inhibition of carrageenan-induced LPA production in pouch fluid at 100 mg/kg, po administered through gavage 1 hr before carrageenan injection measured after 3 hrs by LC-MS/ | 2016 | Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
| Development of Autotaxin Inhibitors: An Overview of the Patent and Primary Literature. |
| AID1908647 | Cytotoxicity against human H2228 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay | 2022 | European journal of medicinal chemistry, Jun-05, Volume: 236 | Design, synthesis and promising anti-tumor efficacy of novel imidazo[1,2-a]pyridine derivatives as potent autotaxin allosteric inhibitors. |
| AID1240355 | Antitumor activity against human MeWo cells xenografted in athymic nude mouse at 30 mg/kg, ip administered every other day of 21 days post tumor cell injection | 2015 | Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
| Vinyl sulfone analogs of lysophosphatidylcholine irreversibly inhibit autotaxin and prevent angiogenesis in melanoma. |
| AID1497191 | Displacement of [3H]dofetilide from human ERG expressed in HEK293 cells after 45 mins by scintillation counting method | 2018 | Bioorganic & medicinal chemistry letters, 07-15, Volume: 28, Issue:13
| Development of autotaxin inhibitors: A series of zinc binding triazoles. |
| AID1480296 | Inhibition of ATX in human whole blood assessed as decrease in LPA levels after 2 hrs by LC-MS/MS method | 2018 | Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
| Hydroxamic Acids Constitute a Novel Class of Autotaxin Inhibitors that Exhibit in Vivo Efficacy in a Pulmonary Fibrosis Model. |
| AID1438631 | In vivo inhibition of ATX in mouse assessed as decrease in eight abundant LPA species level at 10 mg/kg, ip measured after 8 hrs by HPLC electrospray ionization tandem mass spectrometry relative to control | 2017 | Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
| Rational Design of Autotaxin Inhibitors by Structural Evolution of Endogenous Modulators. |
| AID1480295 | Inhibition of recombinant mouse ATX expressed in HEK293 cells using LPC 17:0 as substrate after 30 mins by LC-MS/MS method | 2018 | Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
| Hydroxamic Acids Constitute a Novel Class of Autotaxin Inhibitors that Exhibit in Vivo Efficacy in a Pulmonary Fibrosis Model. |
| AID1908642 | Negative allosteric modulation activity against human ATX using FS-3 as substrate preincubated for 45 mins followed by substrate addition and measured every 30 mins by multi-mode microplate reader | 2022 | European journal of medicinal chemistry, Jun-05, Volume: 236 | Design, synthesis and promising anti-tumor efficacy of novel imidazo[1,2-a]pyridine derivatives as potent autotaxin allosteric inhibitors. |
| AID1312306 | Oral bioavailability in Lewis rat at 1 to 100 mg/kg administered through gavage measured up to 24 hrs by LC-MS/MS analysis | 2016 | Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
| Development of Autotaxin Inhibitors: An Overview of the Patent and Primary Literature. |
| AID1433834 | Inhibition of human ATX expressed in HEK293 cells using FS-3 as substrate preincubated for 15 mins followed by substrate addition measured after 30 mins | 2017 | Journal of medicinal chemistry, 01-26, Volume: 60, Issue:2
| Structure-Activity Relationships of Small Molecule Autotaxin Inhibitors with a Discrete Binding Mode. |
| AID1240356 | Antitumor activity against human MeWo cells xenografted in athymic nude mouse assessed as reduction of ATX level in serum at 30 mg/kg, ip administered every other day of 21 days post tumor cell injection | 2015 | Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
| Vinyl sulfone analogs of lysophosphatidylcholine irreversibly inhibit autotaxin and prevent angiogenesis in melanoma. |
| AID1312307 | Invivo inhibition of ATX in Lewis rat air pouch model of inflammation assessed as inhibition of carrageenan-induced LPA production in plasma at 100 mg/kg, po administered through gavage 1 hr before carrageenan injection measured after 3 hrs by LC-MS/MS an | 2016 | Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
| Development of Autotaxin Inhibitors: An Overview of the Patent and Primary Literature. |
| AID1312303 | Inhibition of recombinant human ATX expressed in HEK293 cells using FS3 as substrate preincubated for 15 mins followed by substrate addition measured after 30 mins | 2016 | Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
| Development of Autotaxin Inhibitors: An Overview of the Patent and Primary Literature. |
| AID1349372 | Inhibition of human full length ATX expressed in HEK cells using FS-3 as substrate incubated for 15 mins followed by substrate addition measured after 30 mins | 2017 | ACS medicinal chemistry letters, Dec-14, Volume: 8, Issue:12
| Discovery of BI-2545: A Novel Autotaxin Inhibitor That Significantly Reduces LPA Levels in Vivo. |
| AID1656151 | Inhibition of human ATX by fluorogenic substrate-3 assay | 2020 | Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13
| Discovery of Novel Indole-Based Allosteric Highly Potent ATX Inhibitors with Great |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1346280 | Human autotaxin (LPA synthesis) | 2010 | The Journal of pharmacology and experimental therapeutics, Jul, Volume: 334, Issue:1
| A novel autotaxin inhibitor reduces lysophosphatidic acid levels in plasma and the site of inflammation. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |